Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients

Transplantation

Volumn 91, Issue 8, 2011, Pages 825-826

  Singh, Nina ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VALGANCICLOVIR;

CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NOTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; T CELL DEPLETION; VIRUS LOAD; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANTIVIRAL AGENTS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RISK ASSESSMENT; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 79954840732     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182126eb9     Document Type: Note

References (13)

1. Helantera I, Kyllonen L, Lautenschlager I, et al. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. San Diego, CA, American Transplant Congress 2010.
2. Limaye A, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645.
3. Doyle AM, Warburton KM, Goral S, et al. 24-Week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
4. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
5. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008; 8: 2111.
6. Kalil AC, Freifeld AG, Lyden ER, et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PloS One 2009; 4: e5512.
7. Emery VC. Prophylaxis for CMV should not now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
8. La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195: 633.
9. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214.
10. BenMarzouk-Hidalgo OJ, Cisneros JM, Cordero E, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during pre-emptive treatment. Transplantation 2011; 91: 927.
11. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202: 585.
12. Zhou Q, Yan J, Putheti P, et al. Isolated CD39 expression on CD4- T cells denotes both regulatory and memory populations. Am J Transplant 2009; 9: 2303.
13. Lilleri D, Fornara C, Chiesa A, et al. Human cytomegalovirus-specific CD4-and CD8-T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008; 93: 248.